GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (STU:31Y) » Definitions » EV-to-EBITDA

Morphic Holding (STU:31Y) EV-to-EBITDA : -4.27 (As of May. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Morphic Holding's enterprise value is €756.99 Mil. Morphic Holding's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-177.35 Mil. Therefore, Morphic Holding's EV-to-EBITDA for today is -4.27.

The historical rank and industry rank for Morphic Holding's EV-to-EBITDA or its related term are showing as below:

STU:31Y' s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.61   Med: -11.37   Max: 4.65
Current: -4.24

During the past 7 years, the highest EV-to-EBITDA of Morphic Holding was 4.65. The lowest was -42.61. And the median was -11.37.

STU:31Y's EV-to-EBITDA is ranked worse than
100% of 454 companies
in the Biotechnology industry
Industry Median: 10.055 vs STU:31Y: -4.24

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-09), Morphic Holding's stock price is €26.60. Morphic Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-3.232. Therefore, Morphic Holding's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Morphic Holding EV-to-EBITDA Historical Data

The historical data trend for Morphic Holding's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding EV-to-EBITDA Chart

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -6.06 -18.38 -14.29 -11.02 -4.14

Morphic Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.36 -14.25 -2.70 -4.14 -5.77

Competitive Comparison of Morphic Holding's EV-to-EBITDA

For the Biotechnology subindustry, Morphic Holding's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morphic Holding's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Morphic Holding's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Morphic Holding's EV-to-EBITDA falls into.



Morphic Holding EV-to-EBITDA Calculation

Morphic Holding's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=756.986/-177.354
=-4.27

Morphic Holding's current Enterprise Value is €756.99 Mil.
Morphic Holding's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-177.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding  (STU:31Y) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Morphic Holding's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=26.60/-3.232
=At Loss

Morphic Holding's share price for today is €26.60.
Morphic Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.232.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Morphic Holding EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Morphic Holding's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding (STU:31Y) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Morphic Holding (STU:31Y) Headlines

No Headlines